Applied Genetic Loss Widens - Quick Facts

(RTTNews) - Applied Genetic Technologies Corp (AGTC) Friday reported fourth-quarter net loss of $4.5 million or $0.32 per share compared with a loss of $1.4 million or $13.10 per share last year.

Applied Genetic is a clinical stage biotechnology company developing adeno-associated virus-based gene therapies for the treatment of rare eye diseases.

The company's revenues for the quarter were $124 thousand compared with $377 thousand in the prior year.

Analysts polled by Thomson Reuters estimated a loss of $0.35 per share on revenues of $100 thousand for the quarter. Analysts' estimates typically exclude special items.

Operating expenses for the quarter climbed to $4.5 million from $1.7 million a year ago, due to higher research and general expenses.